11 results on '"Angueira, T"'
Number of results to display per page
Search Results
2. Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study
- Author
-
Molina-Infante, J., Lucendo, A. J., Angueira, T., Rodriguez-Tellez, M., Perez-Aisa, A., Balboa, A., Barrio, J., Martin-Noguerol, E., Gomez-Rodriguez, B. J., Botargues-Bote, J. M., Gomez-Camarero, J., Huerta, A., Modolell, I., Ariño, I., Herranz-Bachiller, M. T., Bermejo, F., McNicholl, A. G., OʼMorain, C., Gisbert, J. P., Lima, A., Tejero-Bustos, M. A., Sans, M., Mearin, F., Perez-Lasala, J., Mañas-Gallardo, N., Millastre, J., Gracia, M., Rodriguez-Sanchez, J., Rancel-Medina, F. J., Lanas, A., and Prados, S.
- Published
- 2015
- Full Text
- View/download PDF
3. Low adhesion to latent tuberculosis (TB) screening recommendations in inflammatory bowel disease (IBD) patients: Results of the INFEII registry of GETECCU
- Author
-
Abdo, YZ, de Francisco, R, Rodriguez-Lago, I, Chaparro, M, Gomollon, F, Piqueras, M, Llao, J, Sicilia, B, Domenech, E, Garcia-Bosch, O, de Castro, L, Calvet, X, Morales, V, Rivero, M, Lucendo, AJ, Navarro, P, Marquez, L, Busquets, D, Guardiola, J, Gordillo, J, Iglesias, E, Beltran, B, Sese, E, Ferreiro-Iglesias, R, Francisco, M, Pajares, R, Algaba, A, Vicente, R, Benitez, O, Aceituno, M, Riestra, S, Rodriguez-Pescador, A, Gisbert, JP, Arroyo, MT, Mena, R, Sainz, E, Arias-Garcia, L, Manosa, M, Navarro, M, Sanroman, L, Villoria, A, Delgado-Villena, P, Garcia, MJ, Angueira, T, Minguez, M, Murciano, F, Arajol, C, and Esteve, M
- Published
- 2020
4. Drug consumption and additional risk factors associated with microscopic colitis: case-control study
- Author
-
Guagnozzi, D., Lucendo, A. J., Angueira, T., González-Castillo, S., and Jose Maria Tenias
- Subjects
Adult ,Male ,Drug intake ,Anti-Inflammatory Agents, Non-Steroidal ,Fructose ,Microscopic colitis ,Middle Aged ,Autoimmune Diseases ,Colitis, Microscopic ,Irritable bowel syndrome ,Logistic Models ,Neuroprotective Agents ,Risk Factors ,Topiramate ,Case-Control Studies ,Humans ,Female ,lcsh:Diseases of the digestive system. Gastroenterology ,Prospective Studies ,lcsh:RC799-869 ,Chronic diarrhoea ,Aged - Abstract
Background: Microscopic colitis has now emerged as a common cause of chronic diarrhoea, but its aetiology remains unknown. Some studies suggest that commonly prescribed drugs and other additional risk factors may be triggers. Aims: To evaluate the effects of drug intake and other risk factors on microscopic colitis patients. Methods: A prospective, case-control study with all consecutive adult patients referred to the Hospital General de Tomelloso (Ciudad Real, Spain) for chronic watery diarrhoea (from 2008 to 2011) was performed. Microscopic colitis was diagnosed following the commonly accepted histopathological criteria. Results: 46 consecutive new cases of microscopic colitis and 317 chronic diarrhoea controls were recruited. Five independent risk factors significantly associated with microscopic colitis were identified: Abdominal pain (OR 3.25; 95%CI, 1.49-7.08), weight loss (OR 2.67; 95%CI, 1.16-6.15), celiac disease (OR 15.3; 95%CI, 3.70-63.5), topiramate intake (OR 13.6; 95%CI, 1.84-100.8), and older age at diagnosis (OR 1 year increase 1.022; 95%CI, 1.002-1.042). Use of non-steroidal anti-inflammatory drugs was associated with microscopic colitis in the subgroup of patients who fulfilled irritable bowel syndrome criteria (38.5% vs. 10.8%; p < 0.017). Conclusions: Microscopic colitis is associated with autoimmune disease, an increased age at diagnosis, topiramate intake and only in a sub-group of irritable bowel disease patients with non-steroidal anti-inflammatory drugs.
- Published
- 2015
5. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial
- Author
-
Chaparro, María, primary, Donday, María G., additional, Barreiro-de Acosta, Manuel, additional, Domènech, Eugeni, additional, Esteve, María, additional, García-Sánchez, Valle, additional, Nos, Pilar, additional, Panés, Julián, additional, Martínez, Concepción, additional, Gisbert, Javier P., additional, Abad, F., additional, Aguas Peris, M., additional, Agüero Tejado, E., additional, Alba, C., additional, Albert, M., additional, Alemán, H., additional, Algaba, A., additional, Alonso Abreu, I., additional, Amador, M.P., additional, Amat, M., additional, Angueira, T., additional, Arajol, C., additional, Arias-González, L., additional, Arrondo Velasco, A., additional, Baldán, M., additional, Bardán García, B., additional, Bargalló García, A., additional, Barreiro de Acosta, M., additional, Barrio Andrés, J., additional, Bastida Paz, G., additional, Bastón Rey, I., additional, Batista, L., additional, Bellver Martínez, M., additional, Beltrán Niclós, B., additional, Benítez, J.M., additional, Ber Nieto, Y., additional, Bermejo, F., additional, Bernardo, D., additional, Blázquez Gómez, I., additional, Bouhmidi Assakali, A., additional, Busquets Casals, D., additional, Cabriada Nuño, J.L., additional, Calvet Calvo, X., additional, Calvo Hernández, M.V., additional, Calvo, M., additional, Camps, B., additional, Carbajo, A.Y., additional, Cardona Peitx, G., additional, Caro-Patón, T., additional, Carrillo Palau, M., additional, Carrión Bolorino, S., additional, Casanova, M.J., additional, Casellas Valdé, J.A., additional, Castaño García, A., additional, Castro Senosiain, B., additional, Ceballos, D., additional, Cerrillo, E., additional, Chacón Martínez, S., additional, Consuelo Cañete Pizarro, F., additional, de Castro Parga, M.L., additional, de Miguel, M., additional, de Francisco García, R., additional, de la Cruz Ramírez, M.D., additional, del Hoyo Francisco, J., additional, Delgado Guillena, P., additional, Desongles Corrales, T., additional, Echarri Piudo, A., additional, Espino Paisan, E., additional, Espona Quer, M., additional, Fernández Pordomingo, A., additional, Fernández Forcelledo, J.L., additional, Fernández-Tomé, S., additional, Ferreiro Iglesias, R., additional, Ferrer Bradley, I., additional, Ferrer, A., additional, Figueroa, A., additional, Gallach Montero, M., additional, García Iglesias, P., additional, García García-Lezcún, C., additional, García Ramírez, L., additional, García García, M.J., additional, García-Bosh, O., additional, Garre, A., additional, Giménez Poderós, T., additional, Gómez Irwin, L., additional, Gómez Pastrana, B., additional, Gómez Delgado, E., additional, González Lama, Y., additional, Gracia García, Á., additional, Gracia García, B., additional, Guardiola, J., additional, Guerra, I., additional, Guerra, E., additional, Guillot, V., additional, Gustmancher Saiz, S., additional, Gutiérrez Casbas, A., additional, Hernández Ramírez, V., additional, Hernando Verdugo, M.M., additional, Hernández Muniesa, B., additional, Hernanz Chaves, R., additional, Herrera Justiniano, J.M., additional, Hinojosa del Val, J, additional, Ibáñez Feijoo, S, additional, Iborra Colomino, M, additional, Iglesias Flores, E, additional, Izquierdo García, E., additional, Sampedro González, M J, additional, Lucendo, A J., additional, Jiménez García, N, additional, Leo Carnerero, E., additional, Loizaga Díaz, I., additional, López de Torre Querejazu, A, additional, López Sánchez, P, additional, Luis Parras, J, additional, Maia Boscá, M, additional, Mañosa, M, additional, Marín Pedrosa, S, additional, Marín, A, additional, Marinero, Á, additional, Marín-Jiménez, I, additional, Márquez Mosquera, L, additional, Márquez Galán, JL, additional, Martín Arranz, E, additional, Martín Arranz, MD, additional, Martínez Cadilla, J, additional, Martínez Sesmero, JM, additional, Martínez Sánchez, B, additional, Matallana, V, additional, Mateos Hernández, MI, additional, McNicholl, AG, additional, Mejuto Fernández, R, additional, Melcarne, L, additional, Menchén, L, additional, Méndez-Castrillón Rodríguez, J, additional, Merino Ochoa, O, additional, Mínguez, M, additional, Molas Ferrer, G, additional, Montoro Huguet, M, additional, Montserrat Torres, A, additional, Mora, F, additional, Moraleja Yudego, I, additional, Morales Alvarado, VJ, additional, Morales Martínez, L, additional, Morell, A, additional, Motos García, C, additional, Muñoz Alonso, F, additional, Muñoz Villafranca, MC, additional, Muñoz, JE, additional, Mur, A, additional, Nantes, Ó, additional, Navarro, P, additional, Navarro- Llavat, M, additional, Nos Mateu, P, additional, Núñez Alonso, A, additional, Núñez Ortiz, A, additional, Olivares, D, additional, Ollero Pena, V, additional, Orobitg, J, additional, Ortega, L, additional, Ortiz de Zárate, J, additional, Pallarés Manrique, H, additional, Paradela Carreiro, A, additional, Peral Ballester, L, additional, Pereira Bueno, S, additional, Pérez Martínez, I, additional, Pineda Mariño, JR, additional, Piñero Pérez, C, additional, Planas Giner, A, additional, Plaza Santos, MR, additional, Ponferrada Díaz, Á, additional, Poza Cardón, J, additional, Prieto Vicente, V, additional, Puchades, L, additional, Ramos López, L, additional, Redondo, S, additional, Riestra Menéndez, S, additional, Rivero Tirado, M, additional, Rodríguez Lago, I, additional, Rodríguez Gutiérrez, C, additional, Rodríguez, E, additional, Romero Izquierdo, S, additional, Rubio Iturria, S, additional, Ruiz Antorán, MB, additional, Ruiz, A, additional, Salazar, LF, additional, Sánchez Ulayar, A, additional, Sánchez Gómez, E, additional, Sánchez, C, additional, Sangrador, C, additional, Serra, K, additional, Spicakova, K, additional, Suárez Ferrer, C, additional, Talavera Fabuel, A, additional, Taxonera, C, additional, Tordera, M, additional, Torrella Cortés, E, additional, Tosca, J, additional, Trigo Salado, C, additional, Uriarte Estefanía, F, additional, Van Domselaar, M, additional, Vázquez Morón, JM, additional, Ventura López, P, additional, Vera, M, additional, Vicuña Arregui, M, additional, Villoria Ferrer, A, additional, Virgós Aller, T, additional, and Yáñez Feria, D, additional
- Published
- 2019
- Full Text
- View/download PDF
6. Helicobacter pylorisecond-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments
- Author
-
Gisbert, J. P., primary, Romano, M., additional, Gravina, A. G., additional, Solís-Muñoz, P., additional, Bermejo, F., additional, Molina-Infante, J., additional, Castro-Fernández, M., additional, Ortuño, J., additional, Lucendo, A. J., additional, Herranz, M., additional, Modolell, I., additional, del Castillo, F., additional, Gómez, J., additional, Barrio, J., additional, Velayos, B., additional, Gómez, B., additional, Domínguez, J. L., additional, Miranda, A., additional, Martorano, M., additional, Algaba, A., additional, Pabón, M., additional, Angueira, T., additional, Fernández-Salazar, L., additional, Federico, A., additional, Marín, A. C., additional, and McNicholl, A. G., additional
- Published
- 2015
- Full Text
- View/download PDF
7. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments
- Author
-
Manuel Castro-Fernandez, Maurizio Romano, Jose Luis Domínguez, Fernando Bermejo, M. Pabón, Teresa Angueira, M..T. Herranz, Alicia C Marin, Luis Fernández-Salazar, Benito Velayos, Blas J. Gomez, Marco Martorano, Antonietta Gerarda Gravina, Adrian G. McNicholl, Alfredo J. Lucendo, Alicia Algaba, Alessandro Federico, P. Solís-Muñoz, Javier Molina-Infante, J. Gomez, Juan Ortuño, Agnese Miranda, F. del Castillo, Ines Modolell, Jesus Barrio, Javier P. Gisbert, Gisbert, Jp, Romano, Marco, Gravina, Ag, Solís Muñoz, P, Bermejo, F, Molina Infante, J, Castro Fernández, M, Ortuño, J, Lucendo, Aj, Herranz, M, Modolell, I, Del Castillo, F, Gómez, J, Barrio, J, Velayos, B, Gómez, B, Domínguez, Jl, Miranda, A, Martorano, M, Algaba, A, Pabón, M, Angueira, T, Fernández Salazar, L, Federico, Alessandro, Marín, Ac, and Mcnicholl, Ag
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,Gastroenterology ,bacterial infections and mycoses ,Surgery ,Esomeprazole ,Regimen ,Pharmacotherapy ,Tolerability ,Levofloxacin ,Internal medicine ,Concomitant ,Clarithromycin ,medicine ,Pharmacology (medical) ,business ,Adverse effect ,medicine.drug - Abstract
Summary Background The most commonly used second-line Helicobacter pylori eradication regimens are bismuth-containing quadruple therapy and levofloxacin-containing triple therapy, both offering suboptimal results. Combining bismuth and levofloxacin may enhance the efficacy of rescue eradication regimens. Aims To evaluate the efficacy and tolerability of a second-line quadruple regimen containing levofloxacin and bismuth in patients whose previous H. pylori eradication treatment failed. Methods This was a prospective multicenter study including patients in whom a standard triple therapy (PPI–clarithromycin–amoxicillin) or a non-bismuth quadruple therapy (PPI–clarithromycin–amoxicillin–metronidazole, either sequential or concomitant) had failed. Esomeprazole (40 mg b.d.), amoxicillin (1 g b.d.), levofloxacin (500 mg o.d.) and bismuth (240 mg b.d.) was prescribed for 14 days. Eradication was confirmed by 13C-urea breath test. Compliance was determined through questioning and recovery of empty medication envelopes. Incidence of adverse effects was evaluated by questionnaires. Results 200 patients were included consecutively (mean age 47 years, 67% women, 13% ulcer). Previous failed therapy included: standard clarithromycin triple therapy (131 patients), sequential (32) and concomitant (37). A total of 96% took all medications correctly. Per-protocol and intention-to-treat eradication rates were 91.1% (95%CI = 87–95%) and 90% (95%CI = 86–94%). Cure rates were similar regardless of previous (failed) treatment or country of origin. Adverse effects were reported in 46% of patients, most commonly nausea (17%) and diarrhoea (16%); 3% were intense but none was serious. Conclusions Fourteen-day bismuth- and levofloxacin-containing quadruple therapy is an effective (≥90% cure rate), simple and safe second-line strategy in patients whose previous standard triple or non-bismuth quadruple (sequential or concomitant) therapies have failed.
- Published
- 2015
8. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments
- Author
-
Monica Perona, Agnese Miranda, Inés Ariño, Judith Gomez-Camarero, Marco Romano, Luis Ferrer-Barceló, Jesús Barrio, Judith Millastre, Blas J. Gomez, Fernando Bermejo, Ángeles Pérez-Aisa, Juan Ortuño, Ines Modolell, Pedro Almela, Antonietta Gerarda Gravina, Nuria Fernández, Marco Martorano, Adrian G. McNicholl, Alfredo J. Lucendo, Jose Luis Domínguez, Teresa Angueira, Elisa Martin-Noguerol, Enrique Medina, Javier Molina-Infante, Javier P. Gisbert, Juan Enrique Domínguez-Muñoz, Manuel Rodríguez-Tellez, Miguel Fernández-Bermejo, Alessandro Federico, Alicia C Marin, Gisbert, Jp, Romano, Marco, Molina Infante, J, Lucendo, Aj, Medina, E, Modolell, I, Rodríguez Tellez, M, Gomez, B, Barrio, J, Perona, M, Ortuño, J, Ariño, I, Domínguez Muñoz, Je, Perez Aisa, Á, Bermejo, F, Domínguez, Jl, Almela, P, Gomez Camarero, J, Millastre, J, Martin Noguerol, E, Gravina, Ag, Martorano, M, Miranda, A, Federico, Alessandro, Fernandez Bermejo, M, Angueira, T, Ferrer Barcelo, L, Fernández, N, Marín, Ac, and Mcnicholl, Ag
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.drug_class ,Moxifloxacin ,Failure ,Proton-pump inhibitor ,Levofloxacin ,Quinolones ,Gastroenterology ,Esomeprazole ,Helicobacter Infections ,Cohort Studies ,Internal medicine ,medicine ,Humans ,Urea ,Prospective Studies ,Treatment Failure ,Adverse effect ,Eradication ,Hepatology ,Helicobacter pylori ,business.industry ,Amoxicillin ,Proton Pump Inhibitors ,Middle Aged ,Surgery ,Anti-Bacterial Agents ,Regimen ,Treatment Outcome ,Tolerability ,Breath Tests ,Rescue ,Concomitant ,Retreatment ,Drug Therapy, Combination ,Female ,Therapy ,business ,medicine.drug ,Fluoroquinolones - Abstract
Background: Aim was to evaluate the efficacy and tolerability of a moxifloxacin-containing second-line triple regimen in patients whose previous Helicobacter pylori eradication treatment failed. Methods: Prospective multicentre study including patients in whom a triple therapy or a non-bismuth-quadruple- therapy failed. Moxifloxacin (400 mg qd), amoxicillin (1 g bid), and esomeprazole (40 mg bid) were prescribed for 14 days. Eradication was confirmed by C-13-urea-breath-test. Compliance was determined through questioning and recovery of empty medication envelopes. Results: 250 patients were consecutively included (mean age 48 +/- 15 years, 11% with ulcer). Previous (failed) therapy included: standard triple (n = 179), sequential (n = 27), and concomitant (n = 44); 97% of patients took all medications, 4 were lost to follow-up. Intention-to-treat and per-protocol eradication rates were 82.4% (95% CI, 77-87%) and 85.7% (95% CI, 81-90%). Cure rates were similar independently of diagnosis (ulcer, 77%; dyspepsia, 82%) and previous treatment (standard triple, 83%; sequential, 89%; concomitant, 77%). At multivariate analysis, only age was associated with eradication (OR = 0.957; 95% CI, 0.933-0.981). Adverse events were reported in 25.2% of patients: diarrhoea (9.6%), abdominal pain (9.6%), and nausea (9.2%). Conclusion: 14-day moxifloxacin-containing triple therapy is an effective and safe second-line strategy in patients whose previous standard triple therapy or non-bismuth quadruple (sequential or concomitant) therapy has failed, providing a simple alternative to bismuth quadruple regimen. (C) 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
- Published
- 2014
9. Poor Sensitivity of Fecal Gluten Immunogenic Peptides and Serum Antibodies to Detect Duodenal Mucosal Damage in Celiac Disease Monitoring.
- Author
-
Laserna-Mendieta EJ, Casanova MJ, Arias Á, Arias-González L, Majano P, Mate LA, Gordillo-Vélez CH, Jiménez M, Angueira T, Tébar-Romero E, Carrillo-Ramos MJ, Tejero-Bustos MÁ, Gisbert JP, Santander C, and Lucendo AJ
- Subjects
- Adolescent, Adult, Female, Humans, Male, Monitoring, Physiologic, Prospective Studies, Antibodies blood, Celiac Disease blood, Duodenum metabolism, Feces, Glutens metabolism, Intestinal Mucosa metabolism, Peptides metabolism, Surveys and Questionnaires
- Abstract
A lifelong gluten-free diet (GFD) is the only current treatment for celiac disease (CD), but strict compliance is complicated. Duodenal biopsies are the "gold standard" method for diagnosing CD, but they are not generally recommended for disease monitoring. We evaluated the sensitivity and specificity of fecal gluten immunogenic peptides (GIPs) to detect duodenal lesions in CD patients on a GFD and compared them with serum anti-tissue transglutaminase (tTG) IgA antibodies. A prospective study was conducted at two tertiary centers in Spain on a consecutive series of adolescents and adults with CD who maintained a long-lasting GFD. Adherence to a GFD and health-related quality of life were scored with validated questionnaires. Mucosal damage graded according to the Marsh-Oberhüber classification (Marsh 1/2/3) was used as the reference standard. Of the 97 patients included, 27 presented duodenal mucosal damage and 70 had normal biopsies (Marsh 0). The sensitivity (33%) and specificity (81%) of GIPs were similar to those provided by the two assays used to measure anti-tTG antibodies. Scores in questionnaires showed no association with GIP, but an association between GIPs and patients' self-reported gluten consumption was found ( p = 0.003). GIP displayed low sensitivity but acceptable specificity for the detection of mucosal damage in CD.
- Published
- 2020
- Full Text
- View/download PDF
10. European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain.
- Author
-
Caldas M, Pérez-Aisa Á, Castro-Fernández M, Bujanda L, Lucendo AJ, Rodrigo L, Huguet JM, Pérez-Lasala J, Molina-Infante J, Barrio J, Fernández-Salazar L, Lanas Á, Perona M, Domínguez-Cajal M, Ortuño J, Gómez-Rodríguez BJ, Almela P, Botargués JM, Núñez Ó, Modolell I, Gómez J, Ruiz-Zorrilla R, De la Coba C, Huerta A, Iyo E, Pozzati L, Antón R, Barenys M, Angueira T, Fernández-Bermejo M, Campillo A, Alcedo J, Pajares-Villaroya R, Mego M, Bermejo F, Dominguez-Jiménez JL, Titó L, Fernández N, Pabón-Carrasco M, Cosme Á, Mata-Romero P, Alcaide N, Ariño I, Di Maira T, Garre A, Puig I, Nyssen OP, Megraud F, O'Morain C, and Gisbert JP
- Abstract
The management of Helicobacter pylori infection has to rely on previous local effectiveness due to the geographical variability of antibiotic resistance. The aim of this study was to evaluate the effectiveness of first and second-line H. pylori treatment in Spain, where the empirical prescription is recommended. A multicentre prospective non-interventional registry of the clinical practice of European gastroenterologists concerning H. pylori infection (Hp-EuReg) was developed, including patients from 2013 until June 2019. Effectiveness was evaluated descriptively and through a multivariate analysis concerning age, gender, presence of ulcer, proton-pump inhibitor (PPI) dose, therapy duration and compliance. Overall, 53 Spanish hospitals were included, and 10,267 patients received a first-line therapy. The best results were obtained with the 10-day bismuth single-capsule therapy (95% cure rate by intention-to-treat) and with both the 14-day bismuth-clarithromycin quadruple (PPI-bismuth-clarithromycin-amoxicillin, 91%) and the 14-day non-bismuth quadruple concomitant (PPI-clarithromycin-amoxicillin-metronidazole, 92%) therapies. Second-line therapies were prescribed to 2448 patients, with most-effective therapies being the triple quinolone (PPI-amoxicillin-levofloxacin/moxifloxacin) and the bismuth-levofloxacin quadruple schemes (PPI-bismuth-levofloxacin-amoxicillin) prescribed for 14 days (92%, 89% and 90% effectiveness, respectively), and the bismuth single-capsule (10 days, 88.5%). Compliance, longer duration and higher acid inhibition were associated with higher effectiveness. "Optimized" H. pylori therapies achieve over 90% success in Spain.
- Published
- 2020
- Full Text
- View/download PDF
11. [Information for patients. Esophagitis induced by drugs].
- Author
-
Angueira T and Lucendo AJ
- Subjects
- Anti-Bacterial Agents adverse effects, Anti-Inflammatory Agents adverse effects, Diphosphonates adverse effects, Esophagitis diagnosis, Esophagitis therapy, Humans, Esophagitis chemically induced
- Published
- 2015
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.